Article

Vitamin C as an Antioxidant: Evaluation of Its Role in Disease Prevention

Molecular and Clinical Nutrition Section, Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.
Journal of the American College of Nutrition (Impact Factor: 1.68). 03/2003; 22(1):18-35. DOI: 10.1080/07315724.2003.10719272
Source: PubMed

ABSTRACT Vitamin C in humans must be ingested for survival. Vitamin C is an electron donor, and this property accounts for all its known functions. As an electron donor, vitamin C is a potent water-soluble antioxidant in humans. Antioxidant effects of vitamin C have been demonstrated in many experiments in vitro. Human diseases such as atherosclerosis and cancer might occur in part from oxidant damage to tissues. Oxidation of lipids, proteins and DNA results in specific oxidation products that can be measured in the laboratory. While these biomarkers of oxidation have been measured in humans, such assays have not yet been validated or standardized, and the relationship of oxidant markers to human disease conditions is not clear. Epidemiological studies show that diets high in fruits and vegetables are associated with lower risk of cardiovascular disease, stroke and cancer, and with increased longevity. Whether these protective effects are directly attributable to vitamin C is not known. Intervention studies with vitamin C have shown no change in markers of oxidation or clinical benefit. Dose concentration studies of vitamin C in healthy people showed a sigmoidal relationship between oral dose and plasma and tissue vitamin C concentrations. Hence, optimal dosing is critical to intervention studies using vitamin C. Ideally, future studies of antioxidant actions of vitamin C should target selected patient groups. These groups should be known to have increased oxidative damage as assessed by a reliable biomarker or should have high morbidity and mortality due to diseases thought to be caused or exacerbated by oxidant damage.

Download full-text

Full-text

Available from: Peter Eck, Jul 30, 2015
8 Followers
 · 
950 Views
  • Source
    • ", vitamin A [36], vitamin C [35] [37], beta carotene [38], n-3 polyunsaturated fatty acids (PUFA) [39], ramipril [40], selenium [41]). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Previous meta-analyses of interventional trials with vitamin E provided negative results but it remains unclear if this vitamin has some influence on cardiovascular events when supplemented alone. The aim of this study was to compare the effect of vitamin E alone or in combination with other antioxidants on myocardial infarction. Pubmed, ISI Web of Science, SCOPUS and Cochrane database were searched without language restrictions. We investigated randomized clinical trials studying the effect of vitamin E supplementation on myocardial infarction. Sixteen randomized controlled trials of vitamin E treatment were analyzed in this meta-analysis. The dose range for vitamin E was 33-800IU. Follow-up ranged from 0.5 to 9.4 years. Compared to controls, vitamin E given alone significantly decreased myocardial infarction (3.0% vs 3.4%) (random effects R.R.: 0.82; 95% C.I., 0.70-0.96; p = 0.01). This effect was driven by reduction of fatal myocardial infarction (random effects R.R.: 0.84; 95% C.I., 0.73-0.96; p = 0.01). When supplemented alone, vitamin E reduces myocardial infarction in interventional trials while it appears ineffective when associated with other antioxidants. Copyright © 2015 Elsevier B.V. All rights reserved.
    Nutrition Metabolism and Cardiovascular Diseases 02/2015; 25(4). DOI:10.1016/j.numecd.2015.01.008 · 3.88 Impact Factor
  • Source
    • "L-Ascorbic acid, a well-known antioxidant, is commonly used in many foods and cosmetics as an anti-oxidizing agent (Padayatty et al., 2003). It functions as both a reducing agent and a free radical scavenger by donating either one or two electrons to more oxidized neighbouring compounds. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A mutant derived from a cyclodextrin glucantransferase with an alanine residue as its acid/base catalyst residue (CGT-E284A) catalyzed regioselective glycosylation at 3-OH of l-ascorbic acid using α-maltosyl fluoride (αG2F) and l-ascorbic acid as the donor and acceptor, respectively, yielding 3-O-α-maltosyl-l-ascorbate (AA3αG2). The optimum conditions were determined by high-performance liquid chromatography analysis with 20 mM αG2F and 40 mM l-ascorbic acid as the substrates at pH 7.5 and 25 °C with 1 mg/ml of the enzyme for 24 h. Calcium ions bound in CGT-E284A played an important role in the transglycosylation. CGT-E284A exhibited typical saturation kinetic behaviour for αG2F at a fixed acceptor concentration (40 mM), and substrate inhibition by l-ascorbic acid was observed at high l-ascorbic acid concentrations (>60 mM). AA3αG2 was isolated from a preparative scale reaction with a yield of 29%, and it showed extremely high stability under oxidative conditions.
    Food Chemistry 02/2015; 169:366–371. DOI:10.1016/j.foodchem.2014.07.110 · 3.26 Impact Factor
  • Source
    • "Ascorbic acid (AA) is one of the most studied antioxidants; it is highly concentrated in the adrenal gland and central nervous system (Miura et al., 2009), with postulated important action during brain development (Zalani et al., 1989). The physiological actions of AA include protection against oxidative stress, with possible protective actions in neurodegenerative diseases (Halliwell, 2006; Padayatty et al., 2003). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Although ascorbic acid (AA) is an antioxidant, under certain conditions it can facilitate oxidation, which may underlie the opposite actions of AA on brain excitability in distinct seizure models. Here, we investigated whether chronic AA administration during brain development alters cortical excitability as a function of AA dose, as indexed by cortical spreading depression (CSD) and by the levels of lipid peroxidation-induced malondialdehyde. Well-nourished and early-malnourished rats received per gavage 30, 60, or 120 mg/kg/d of AA, saline, or no gavage treatment (naïve group) at postnatal days 7-28. CSD propagation and malondialdehyde levels were analyzed at 30-40 days. Confirming previous observations, CSD velocities were significantly higher in the early-malnourished groups than in the well-nourished groups. AA dose was important: 30 mg/kg/d AA decelerated CSD and reduced malondialdehyde levels, whereas 60 mg/kg/d and 120 mg/kg/d accelerated CSD and augmented malondialdehyde levels compared with the corresponding saline and naïve groups. Our findings reinforce previous suggestion that AA acts as an antioxidant in the brain when administered at low doses, but as a prooxidant at high doses, as indicated by CSD propagation and malondialdehyde levels.
    Neuropharmacology 07/2014; 86. DOI:10.1016/j.neuropharm.2014.06.027 · 4.82 Impact Factor
Show more